Provided by Tiger Fintech (Singapore) Pte. Ltd.

Schrodinger Inc.

20.32
+0.73503.75%
Pre-market: 20.12-0.1950-0.96%08:27 EDT
Volume:1.90M
Turnover:38.11M
Market Cap:1.50B
PE:-8.18
High:20.45
Open:19.86
Low:19.50
Close:19.58
52wk High:28.47
52wk Low:16.60
Shares:73.61M
Float Shares:57.82M
Volume Ratio:1.60
T/O Rate:3.28%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4826
EPS(LYR):-2.5750
ROE:-44.40%
ROA:-17.52%
PB:4.36
PE(LYR):-7.89

Loading ...

BRIEF-Schrödinger Reports Inducement Grants

Reuters
·
Aug 16

Schrödinger Inc. Announces New Inducement Equity Incentive Plan with RSUs for New Employees

Reuters
·
Aug 16

SchrÖDinger Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Aug 16

Citigroup Downgrades Schrodinger to Neutral From Buy, Adjusts Price Target to $20 From $35

MT Newswires Live
·
Aug 15

Schrodinger Cut to Neutral From Buy by Citigroup

Dow Jones
·
Aug 15

Schrodinger Inc : Citigroup Cuts to Neutral From Buy; Cuts Target Price to $20 From $35

THOMSON REUTERS
·
Aug 15

Schrodinger downgraded to Neutral from Buy at Citi

TIPRANKS
·
Aug 15

Schrodinger’s Hold Rating: Challenges in Drug Pipeline and Software Growth Amid Macroeconomic Headwinds

TIPRANKS
·
Aug 15

BUZZ-U.S. STOCKS ON THE MOVE-Oracle, Kratos, Masimo

Reuters
·
Aug 14

Schrodinger Shares Fall 9.4% After Co Says It Will Stop Development of a Blood Cancer Therapy Due to 2 Patient Deaths in Trial

THOMSON REUTERS
·
Aug 14

Schrodinger Shares Fall 17.2% Premarket After Co Says It Will Stop Blood Cancer Therapy Development on Patient Deaths

THOMSON REUTERS
·
Aug 14

BUZZ-Schrodinger falls after ending blood cancer therapy development on patient deaths

Reuters
·
Aug 14

BRIEF-Schrödinger Discontinues Development Of Sgr-2921 Cdc7 Inhibitor

Reuters
·
Aug 14

Schrodinger Discontinues SGR-2921 Program Following Deaths of Two AML Patients

MT Newswires Live
·
Aug 14

Barclays Initiates Schrodinger at Overweight With $25 Price Target

MT Newswires Live
·
Aug 14

Schrodinger Inc - SchrÖDinger Discontinues Development of Sgr-2921 Cdc7 Inhibitor

THOMSON REUTERS
·
Aug 14

Schrodinger :  Barclays Initiates Coverage With Overweight Rating and Target Price $25

THOMSON REUTERS
·
Aug 14

BMO Capital Remains a Buy on Schrodinger (SDGR)

TIPRANKS
·
Aug 13

Schrodinger’s Strong Financial Performance and Promising Pipeline Developments Justify Buy Rating

TIPRANKS
·
Aug 08

Stock Track | Schrodinger (SDGR) Surges 5% in Pre-market Following Strong Q2 Results and Positive Outlook

Stock Track
·
Aug 07